Key result
Limb-lead amplitude-duration product ≥0.70 mV s strongly separated hypertrophic cardiomyopathy patients with sudden death or cardiac arrest from the general HCM cohort (OR 31.5; P<0.0001).
Why the study?
Does 12-lead ECG amplitude assessment predict sudden death or cardiac arrest in patients with hypertrophic cardiomyopathy?
Population
194 subjects including 44 normals, 34 athletes, 87 hospital-cohort hypertrophic cardiomyopathy patients, and…
Comparison
12-lead ECG assessment of amplitude sums and… vs Comparison between HCM patients with sudden…
Design
Case-control
Authors
Loading...
May support ECG amplitude metrics for sudden death risk stratification in HCM; leaves open prospective validation before practice change.
Case-Control (n=194)
Does 12-lead ECG amplitude assessment predict sudden death or cardiac arrest in patients with hypertrophic cardiomyopathy?
Effect estimate: OR 31.5
p-value: p=<0.0001
Twelve-lead ECG amplitude sums and amplitude-duration products are strong predictors of sudden death or cardiac arrest in patients with hypertrophic cardiomyopathy.
Östman‐Smith et al. (2009) conducted a case-control in Hypertrophic cardiomyopathy (HCM) (n=194). ECG-amplitude sums and amplitude-duration products vs. HCM-cohort without sudden death/cardiac arrest, normal controls, and athletes was evaluated on Sudden death or cardiac arrest (OR 31.5, p=<0.0001). Limb-lead amplitude-duration product ≥0.70 mV s strongly separated hypertrophic cardiomyopathy patients with sudden death or cardiac arrest from the general HCM cohort (OR 31.5; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: